Prevenar 13

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)

Adult ≥50 yr: Active immunisation for the prevention of pneumonia & invasive disease caused by Strep pneumoniae. Adult 18-49 yr: Active immunisation for the prevention of invasive disease & pneumonia caused by Strep pneumoniae. Infant 6 wk to 17 yr: Active immunisation for the prevention of invasive disease, pneumonia & acute otitis media caused by Strep pneumoniae.

IM 0.5 mL (1 dose). Adult ≥18 yr (including those previously vaccinated w/ pneumococcal polysaccharide vaccine) & elderly Single dose. Unvaccinated childn 2-17 yr Single dose. Infant & childn 12-23 mth 2 doses w/ at least 2-mth interval between doses. Infant 7-11 mth 2 doses w/ at least 1-mth interval between doses; 3rd dose by 2nd yr. Infant 6 wk-6 mth Primary infant series consisting 3 doses w/ 1st dose given at 2 mth; can be given as young as 6 wk w/ at least 1-mth interval between doses, followed by a 4th (booster) dose to be administered at 12-15 mth. Pre-term infant <37 wk gestation Primary infant series consisting 3 doses w/ 1st dose given at 2 mth; can be given as young as 6 wk w/ at least 1-mth interval between doses; followed by a 4th (booster) dose recommended approx at 12 mth. Childn 5-17 yr previously vaccinated w/ ≥1 doses of pneumococcal 7-valent conjugate vaccine Single dose at least 8 wk after final dose. Childn 12-59 mth completely immunised w/ pneumococcal 7-valent conjugate vaccine Single dose at least 8 wk after the final dose. Childn & infant who have started immunisation w/ pneumococcal 7-valent conjugate vaccine May switch to Prevenar 13 at any point in the schedule. Individual who may be at higher risk of pneumococcal infection including those previously vaccinated w/ ≥1 doses of 23-valent pneumococcal polysaccharide vaccine At least 1 dose. Individual w/ hematopoietic stem cell transplant (HSCT) Primary series consisting 3 doses w/ the 1st dose given 3-6 mth after HSCT & w/ an interval of at least 1 mth between doses. Booster dose: 6 mth after the 3rd dose.

Hypersensitivity to pneumococcal polysaccharide conjugate vaccine or to diphtheria toxoid. Postpone administration in patients w/ acute, severe febrile illness.

Do not administer intravascularly or inj intradermally, SC or IV, or in the gluteal area. Different injectable vaccines should be given at different vaccination sites. Patients w/ thrombocytopenia or any coagulation disorder, or to those receiving anticoagulants; impaired immune responsiveness; malignancy, nephrotic syndrome. May not protect all individuals receiving the vaccine from pneumococcal disease. Childn ≥2 yr w/ sickle cell disease, asplenia, HIV infection, chronic illness, or those who are immunocompromised. Consider the potential risk of apnoea & the need of resp monitoring for 48-72 hr when administering primary immunisation to very premature infants (≤28 wk of gestation) & particularly those w/ history of resp immaturity. Concomitant use w/ DTPa-HBV-IPV/Hib vaccine. Initiate antipyretic treatment to childn w/ seizure disorders or w/ history of febrile seizures & for all childn receiving concomitant vaccine containing whole cell pertussis. May temporarily affect the ability to drive or operate machinery. Pregnancy & lactation. Childn <6 wk.

Decreased appetite; fever, vaccination-site erythema, induration/swelling or pain/tenderness. Irritability; drowsiness/increased sleep, restless/decreased sleep. Headache; diarrhea, vomiting (in adults 18-49 yr); rash; generalized new/aggravated joint & muscle pain; chills, fatigue, limitation of arm movement (adults 18-39 yr). Urticaria or urticaria-like rash.

Childn 6 wk-5 yr & infant: May reduce the immune response w/ paracetamol.

Vaccines, Antisera & Immunologicals

J07AL02 - pneumococcus, purified polysaccharides antigen conjugated ; Belongs to the class of pneumococcal bacterial vaccines.

POM